Market Cap ₹1059 Cr.
Stock P/E 10.4
P/B 2.7
Current Price ₹35.3
Book Value ₹ 13.2
Face Value 1
52W High ₹44
Dividend Yield 0%
52W Low ₹ 32.5
Mukka Proteins Limited, established in November 2010, is a leading Indian company in the production of fish meal, fish oil, and fish soluble paste. With its manufacturing units strategically located along the Indian coastline, including Karnataka, Maharashtra, Gujarat, and international locations like the Gulf of Oman and Bangladesh, Mukka Proteins ensures easy access to raw materials. Mukka Proteins is also exploring alternative proteins such as Black Soldier Fly (BSF) insect meal, expanding its portfolio in the animal food segment. The company’s EBITDA has seen a significant increase, indicating robust financial health and growth. Mukka Proteins is known for its commitment to quality assurance and holds various certifications that underscore this dedication. The company went public in February 2024, showcasing its market confidence and potential for further expansion. Mukka Proteins continues to serve a global market, exporting to over 10 countries, and remains a trusted name in the industry.
Price goes above X
Price falls below X
PE goes above X
PE falls below X
₹ | |
| #(Fig in Cr.) | Dec 2022 | Mar 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|
| Net Sales | 397 | 421 | 517 | 257 |
| Other Income | 2 | -0 | 6 | 3 |
| Total Income | 399 | 421 | 523 | 260 |
| Total Expenditure | 362 | 376 | 498 | 225 |
| Operating Profit | 37 | 44 | 25 | 35 |
| Interest | 4 | 7 | 6 | 7 |
| Depreciation | 3 | 3 | 3 | 3 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 |
| Profit Before Tax | 30 | 35 | 16 | 26 |
| Provision for Tax | 6 | 11 | 5 | -2 |
| Profit After Tax | 25 | 24 | 10 | 28 |
| Adjustments | -2 | -2 | 0 | -1 |
| Profit After Adjustments | 23 | 22 | 10 | 27 |
| Adjusted Earnings Per Share | 1 | 1 | 0.5 | 0.9 |
| #(Fig in Cr.) | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM |
|---|---|---|---|---|---|---|
| Net Sales | 409 | 549 | 604 | 771 | 1177 | 1592 |
| Other Income | 3 | 8 | 10 | 7 | 10 | 11 |
| Total Income | 412 | 557 | 614 | 778 | 1187 | 1603 |
| Total Expenditure | 385 | 525 | 582 | 724 | 1093 | 1461 |
| Operating Profit | 26 | 32 | 32 | 54 | 94 | 141 |
| Interest | 4 | 7 | 8 | 10 | 16 | 24 |
| Depreciation | 2 | 5 | 8 | 9 | 12 | 12 |
| Exceptional Income / Expenses | -1 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 19 | 20 | 15 | 36 | 66 | 107 |
| Provision for Tax | 5 | 6 | 4 | 10 | 18 | 20 |
| Profit After Tax | 14 | 14 | 11 | 26 | 48 | 87 |
| Adjustments | 1 | -0 | -2 | -2 | -3 | -5 |
| Profit After Adjustments | 14 | 13 | 9 | 24 | 44 | 82 |
| Adjusted Earnings Per Share | 0.6 | 0.6 | 0.4 | 1.1 | 2 | 3.4 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 53% | 29% | 0% | 0% |
| Operating Profit CAGR | 74% | 43% | 0% | 0% |
| PAT CAGR | 85% | 51% | 0% | 0% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | NA% | NA% | NA% | NA% |
| ROE Average | 39% | 29% | 29% | 29% |
| ROCE Average | 24% | 18% | 18% | 18% |
| #(Fig in Cr.) | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 |
|---|---|---|---|---|---|
| Shareholder's Funds | 44 | 57 | 67 | 98 | 148 |
| Minority's Interest | 0 | 1 | 3 | 5 | 8 |
| Borrowings | 16 | 14 | 9 | 9 | 5 |
| Other Non-Current Liabilities | 3 | 4 | 4 | 6 | 11 |
| Total Current Liabilities | 137 | 217 | 272 | 274 | 403 |
| Total Liabilities | 201 | 293 | 355 | 392 | 575 |
| Fixed Assets | 48 | 77 | 78 | 81 | 83 |
| Other Non-Current Assets | 11 | 10 | 20 | 25 | 27 |
| Total Current Assets | 142 | 206 | 257 | 286 | 465 |
| Total Assets | 201 | 293 | 355 | 392 | 575 |
| #(Fig in Cr.) | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 |
|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 10 | 1 | 1 | 3 | 12 |
| Cash Flow from Operating Activities | -20 | -25 | 2 | 5 | -57 |
| Cash Flow from Investing Activities | -23 | -28 | -14 | -11 | -2 |
| Cash Flow from Financing Activities | 34 | 54 | 13 | 15 | 75 |
| Net Cash Inflow / Outflow | -9 | 1 | 2 | 8 | 15 |
| Closing Cash & Cash Equivalent | 1 | 2 | 3 | 12 | 27 |
| # | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 |
|---|---|---|---|---|---|
| Earnings Per Share (Rs) | 0.65 | 0.6 | 0.41 | 1.1 | 2 |
| CEPS(Rs) | 0.73 | 0.83 | 0.88 | 1.56 | 2.7 |
| DPS(Rs) | 0 | 0 | 0 | 0 | 0 |
| Book NAV/Share(Rs) | 2 | 2.57 | 3.02 | 4.47 | 6.72 |
| Core EBITDA Margin(%) | 5.71 | 4.33 | 3.62 | 6.07 | 7.16 |
| EBIT Margin(%) | 5.66 | 4.9 | 3.89 | 5.93 | 7 |
| Pre Tax Margin(%) | 4.6 | 3.59 | 2.56 | 4.67 | 5.6 |
| PAT Margin (%) | 3.35 | 2.47 | 1.82 | 3.35 | 4.04 |
| Cash Profit Margin (%) | 3.94 | 3.33 | 3.21 | 4.46 | 5.05 |
| ROA(%) | 6.81 | 5.5 | 3.4 | 6.91 | 9.82 |
| ROE(%) | 31.1 | 27 | 17.89 | 31.32 | 38.61 |
| ROCE(%) | 18.24 | 16.57 | 11.08 | 18.35 | 24.44 |
| Receivable days | 25.44 | 21.1 | 25.05 | 25.87 | 28.54 |
| Inventory Days | 80.39 | 68.16 | 80.08 | 74.55 | 61.18 |
| Payable days | 62.95 | 54.51 | 64.49 | 56.82 | 44.32 |
| PER(x) | 0 | 0 | 0 | 0 | 0 |
| Price/Book(x) | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield(%) | 0 | 0 | 0 | 0 | 0 |
| EV/Net Sales(x) | 0.21 | 0.26 | 0.27 | 0.24 | 0.21 |
| EV/Core EBITDA(x) | 3.33 | 4.6 | 5.04 | 3.35 | 2.63 |
| Net Sales Growth(%) | 0 | 34.36 | 9.94 | 27.6 | 52.77 |
| EBIT Growth(%) | 0 | 16.41 | -12.85 | 94.49 | 80.51 |
| PAT Growth(%) | 0 | -0.78 | -18.89 | 134.5 | 84.07 |
| EPS Growth(%) | 0 | -7.8 | -31.88 | 169.71 | 82.06 |
| Debt/Equity(x) | 1.88 | 2.51 | 2.39 | 1.76 | 1.72 |
| Current Ratio(x) | 1.04 | 0.95 | 0.95 | 1.05 | 1.15 |
| Quick Ratio(x) | 0.38 | 0.42 | 0.39 | 0.44 | 0.58 |
| Interest Cover(x) | 5.33 | 3.74 | 2.93 | 4.72 | 5 |
| Total Debt/Mcap(x) | 0 | 0 | 0 | 0 | 0 |
| # | Dec 2023 | Mar 2024 |
|---|---|---|
| Promoter | 73.33 | 73.33 |
| FII | 7.66 | 6.46 |
| DII | 4.59 | 2 |
| Public | 14.42 | 18.2 |
| Others | 0 | 0 |
| Total | 100 | 100 |
| # | Dec 2023 | Mar 2024 |
|---|---|---|
| Promoter | 22 | 22 |
| FII | 2.3 | 1.94 |
| DII | 1.38 | 0.6 |
| Public | 4.33 | 5.46 |
| Others | 0 | 0 |
| Total | 30 | 30 |
Pros
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Sell or Purchase Share (Tentative Price)
| Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
|---|
| Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
|---|
| Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
|---|
| Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
|---|
| Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
|---|
You May Also Know About
